Active, not recruitingPhase 1NCT03628209
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Studying Bone sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Principal Investigator
- Patrick A. Thompson, MDUniversity of North Carolina, Chapel Hill
- Intervention
- Nivolumab(drug)
- Enrollment
- 21 enrolled
- Eligibility
- 39 years · All sexes
- Timeline
- 2019 – 2026
Study locations (22)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Children's Hospital of Los Angeles, USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- Connecticut Children's Medical Center, Hartford, Connecticut, United States
- Alfred I DuPont Hospital for Children, Wilmington, Delaware, United States
- Shand's Hospital for Children at the University of Florida, Gainesville, Florida, United States
- Nemours Children's Hospital, Jacksonville, Florida, United States
- University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Nemours Children's Clinic, Orlando, Florida, United States
- Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
- H. Lee Moffitt Cancer Center and Research Institute, Coordinating Center, Tampa, Florida, United States
- University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States
- Johns Hopkins University, Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
- +7 more locations on ClinicalTrials.gov
Collaborators
Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03628209 on ClinicalTrials.govOther trials for Bone sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07479732Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic OsteosarcomaPeking University People's Hospital
- RECRUITINGPHASE1NCT07222735Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory SarcomasSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07359053MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced SarcomaShanghai 6th People's Hospital
- RECRUITINGPHASE2NCT06939855QL1706 in the Treatment of Advanced Bone and Soft Tissue SarcomaSun Yat-sen University
- RECRUITINGNCT07215611Financial Toxicity in Patients With Resected Soft Tissue and Bone SarcomasM.D. Anderson Cancer Center
- RECRUITINGNCT06958107LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma PatientsWake Forest University Health Sciences
- RECRUITINGPHASE1, PHASE2NCT07066982Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced SarcomasEssen Biotech
- RECRUITINGNANCT06796543Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone SarcomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins